- AC Immune reported a **net loss of CHF 15.9 million** for the three months ended September 30, 2025, compared to a net income of CHF 5.5 million in the comparable 2024 period. This change was primarily due to the recognition of a **CHF 24.6 million milestone payment** from Janssen in Q3 2024.  **[1651625_0001104659-25-105896_aciu-20251104xex99d3.htm:1]** 
- As of September 30, 2025, the company had **cash resources of CHF 108.5 million**, which are projected to fund operations until the **end of Q3 2027**, excluding potential milestone payments.  **[1651625_0001104659-25-105896_aciu-20251104xex99d3.htm:0]** **[1651625_0001104659-25-105896_aciu-20251104xex99d3.htm:1]** 
- Following a strategic review, AC Immune **reduced its workforce by approximately 30%** to focus investments on high-value assets, contributing to the extended cash runway.  **[1651625_0001104659-25-105896_aciu-20251104xex99d3.htm:0]** 
- Research & development (R&D) expenses for Q3 2025 were **CHF 13.1 million**, down from CHF 14.5 million in Q3 2024, while general & administrative (G&A) expenses decreased slightly to **CHF 3.6 million** from CHF 3.8 million in the same periods.  **[1651625_0001104659-25-105896_aciu-20251104xex99d3.htm:1]**

AC Immune (ACIU)